MirSNPs in clopidogrel metabolism genes predict cardiovascular disease risk: A case-control study and meta-analysis

Anu Radha Sharma; Sourav Patagi; Abdul Razak Uk; Ranjan Shetty; Shashikiran Umakanth; Kapaettu Satyamoorthy; Padmalatha S. Rai

doi:10.2217/pgs-2020-0110

MirSNPs in clopidogrel metabolism genes predict cardiovascular disease risk: A case-control study and meta-analysis

Anu Radha Sharma
, Sourav Patagi
, Abdul Razak Uk
, Ranjan Shetty
, Shashikiran Umakanth
, Kapaettu Satyamoorthy
, Padmalatha S. Rai^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Aim: The present study was conducted to decipher the inter-relationship of SNPs and miRNAs involved in pharmacogenomics of clopidogrel on predisposition to cardiovascular diseases (CVDs). Materials & methods: A case-control study was conducted on 410 cases and 386 controls to analyze the association of 13 mirSNPs on CVDs risk. Genotyping was performed by tetra-primer amplification refractory mutation system PCR and validated using Sanger DNA sequencing. miRNA expression analysis was performed using TaqMan assays. A meta-analysis was performed for PON1 rs662 with coronary artery disease. Results & conclusion: PON1 rs662, PON1 rs3917577, CYP3A5 rs15524, COL4A1 rs874204 and PTGIR rs1126510 polymorphisms showed association with CVDs. The miRNA hsa-miR-224-5p showed differential expression in the PON1 rs3917577 GG genotype. The meta-analysis showed the population-specific impact of PON1 rs662 on South Asian and Middle East populations.

Original language	English
Pages (from-to)	99-113
Number of pages	15
Journal	Pharmacogenomics
Volume	22
Issue number	2
DOIs	https://doi.org/10.2217/pgs-2020-0110
Publication status	Published - 01-2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Molecular Medicine
Genetics
Pharmacology

Access to Document

10.2217/pgs-2020-0110

Cite this

@article{35639ab2ca424c1aa89644a9c13e169a,

title = "MirSNPs in clopidogrel metabolism genes predict cardiovascular disease risk: A case-control study and meta-analysis",

abstract = "Aim: The present study was conducted to decipher the inter-relationship of SNPs and miRNAs involved in pharmacogenomics of clopidogrel on predisposition to cardiovascular diseases (CVDs). Materials \& methods: A case-control study was conducted on 410 cases and 386 controls to analyze the association of 13 mirSNPs on CVDs risk. Genotyping was performed by tetra-primer amplification refractory mutation system PCR and validated using Sanger DNA sequencing. miRNA expression analysis was performed using TaqMan assays. A meta-analysis was performed for PON1 rs662 with coronary artery disease. Results \& conclusion: PON1 rs662, PON1 rs3917577, CYP3A5 rs15524, COL4A1 rs874204 and PTGIR rs1126510 polymorphisms showed association with CVDs. The miRNA hsa-miR-224-5p showed differential expression in the PON1 rs3917577 GG genotype. The meta-analysis showed the population-specific impact of PON1 rs662 on South Asian and Middle East populations. ",

author = "Sharma, \{Anu Radha\} and Sourav Patagi and Uk, \{Abdul Razak\} and Ranjan Shetty and Shashikiran Umakanth and Kapaettu Satyamoorthy and Rai, \{Padmalatha S.\}",

note = "Funding Information: The study was supported by Indian Council of Medical Research (ICMR) (no. 3/1/2(16)/CVD/2018-NCD-II), Technology Information Forecasting and Assessment Council-Centre of Relevance and Excellence (TIFAC-CORE) in Pharmacogenomics, Dr. TMA Pai Endowment Chair in Pharmacogenomics, Manipal Academy of Higher Education, Manipal, DST-FIST, Government of India and K-FIST, Government of Karnataka.N Publisher Copyright: {\textcopyright} 2020 Future Medicine Ltd. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = jan,

doi = "10.2217/pgs-2020-0110",

language = "English",

volume = "22",

pages = "99--113",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - MirSNPs in clopidogrel metabolism genes predict cardiovascular disease risk

T2 - A case-control study and meta-analysis

AU - Sharma, Anu Radha

AU - Patagi, Sourav

AU - Uk, Abdul Razak

AU - Shetty, Ranjan

AU - Umakanth, Shashikiran

AU - Satyamoorthy, Kapaettu

AU - Rai, Padmalatha S.

N1 - Funding Information: The study was supported by Indian Council of Medical Research (ICMR) (no. 3/1/2(16)/CVD/2018-NCD-II), Technology Information Forecasting and Assessment Council-Centre of Relevance and Excellence (TIFAC-CORE) in Pharmacogenomics, Dr. TMA Pai Endowment Chair in Pharmacogenomics, Manipal Academy of Higher Education, Manipal, DST-FIST, Government of India and K-FIST, Government of Karnataka.N Publisher Copyright: © 2020 Future Medicine Ltd. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/1

Y1 - 2021/1

N2 - Aim: The present study was conducted to decipher the inter-relationship of SNPs and miRNAs involved in pharmacogenomics of clopidogrel on predisposition to cardiovascular diseases (CVDs). Materials & methods: A case-control study was conducted on 410 cases and 386 controls to analyze the association of 13 mirSNPs on CVDs risk. Genotyping was performed by tetra-primer amplification refractory mutation system PCR and validated using Sanger DNA sequencing. miRNA expression analysis was performed using TaqMan assays. A meta-analysis was performed for PON1 rs662 with coronary artery disease. Results & conclusion: PON1 rs662, PON1 rs3917577, CYP3A5 rs15524, COL4A1 rs874204 and PTGIR rs1126510 polymorphisms showed association with CVDs. The miRNA hsa-miR-224-5p showed differential expression in the PON1 rs3917577 GG genotype. The meta-analysis showed the population-specific impact of PON1 rs662 on South Asian and Middle East populations.

AB - Aim: The present study was conducted to decipher the inter-relationship of SNPs and miRNAs involved in pharmacogenomics of clopidogrel on predisposition to cardiovascular diseases (CVDs). Materials & methods: A case-control study was conducted on 410 cases and 386 controls to analyze the association of 13 mirSNPs on CVDs risk. Genotyping was performed by tetra-primer amplification refractory mutation system PCR and validated using Sanger DNA sequencing. miRNA expression analysis was performed using TaqMan assays. A meta-analysis was performed for PON1 rs662 with coronary artery disease. Results & conclusion: PON1 rs662, PON1 rs3917577, CYP3A5 rs15524, COL4A1 rs874204 and PTGIR rs1126510 polymorphisms showed association with CVDs. The miRNA hsa-miR-224-5p showed differential expression in the PON1 rs3917577 GG genotype. The meta-analysis showed the population-specific impact of PON1 rs662 on South Asian and Middle East populations.

UR - https://www.scopus.com/pages/publications/85099824262

UR - https://www.scopus.com/pages/publications/85099824262#tab=citedBy

U2 - 10.2217/pgs-2020-0110

DO - 10.2217/pgs-2020-0110

M3 - Article

C2 - 33356544

AN - SCOPUS:85099824262

SN - 1462-2416

VL - 22

SP - 99

EP - 113

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 2

ER -

MirSNPs in clopidogrel metabolism genes predict cardiovascular disease risk: A case-control study and meta-analysis

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this